The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer
Open accessAbstract
BACKGROUND: Darolutamide is a potent androgen-receptor inhibitor that has been associated with increased overall survival among patients with nonmetastatic, castration-resistant prostate cancer. Whether a combination of darolutamide, androgen-deprivation therapy, and docetaxel would increase survival among patients with metastatic, hormone-sensitive prostate cancer is unknown. METHODS: In this international, phase 3 trial, we randomly assigned patients with metastatic, hormone-sensitive prostate cancer in a 1:1 ratio to receive darolutamide (at a dose of 600 mg [two 300-mg tablets] twice daily) or matching placebo, both in combination with androgen-deprivation therapy and docetaxel. The primary end point was overall survival. RESULTS: The primary analysis involved 1306 patients (651 in the darolutamide group and 655 in the placebo group); 86.1% of the patients had disease that was metastatic at the time of the initial diagnosis. At the data cutoff date for the primary analysis (October 25, 2021), the risk of death was significantly lower, by 32.5%, in the darolutamide group than in the placebo group (hazard ratio 0.68; 95% confidence interval, 0.57 to 0.80; P<0.001). Darolutamide was also associated with consistent benefits with respect to the secondary end points and prespecified subgroups. Adverse events were similar in the two groups, and the incidences of the most common adverse events (occurring in ≥10% of the patients) were highest during the overlapping docetaxel treatment period in both groups. The frequency of grade 3 or 4 adverse events was 66.1% in the darolutamide group and 63.5% in the placebo group; neutropenia was the most common grade 3 or 4 adverse event (in 33.7% and 34.2%, respectively). CONCLUSIONS: In this trial involving patients with metastatic, hormone-sensitive prostate cancer, overall survival was significantly longer with the combination of darolutamide, androgen-deprivation therapy, and docetaxel than with placebo plus androgen-deprivation therapy and docetaxel, and the addition of darolutamide led to improvement in key secondary end points. The frequency of adverse events was similar in the two groups. (Funded by Bayer and Orion Pharma; ARASENS ClinicalTrials.gov number, NCT02799602.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
Sweeney, C. J., Chen, Y.-H., Carducci, M., Liu, G., Jarrard, D. F., Eisenberger, M., Wong, Y.-N., Hahn, N., Kohli, M., Cooney, M. M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503747 · Cited by 2,896
Self-citationAbiraterone for prostate cancer not previously treated with hormone therapy
James, N. D., de Bono, J. S., Spears, M. R., Clarke, N. W., Mason, M. D., Dearnaley, D. P., Ritchie, A. W. S., Amos, C. L., Gilson, C., Jones, R. J., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1702900 · Cited by 1,801
Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer
Davis, I. D., Martin, A. J., Stockler, M. R., Begbie, S., Chi, K. N., Chowdhury, S., Coskinas, X., Frydenberg, M., Hague, W. E., Horvath, L. G., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1903835 · Cited by 1,633
Self-citationArmstrong, A. J., Szmulewitz, R. Z., Petrylak, D. P., Holzbeierlein, J., Villers, A., Azad, A., Alcaraz, A., Alekseev, B., Iguchi, T., Shore, N. D., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.00799 · Cited by 1,217
Self-citationKyriakopoulos, C. E., Chen, Y.-H., Carducci, M. A., Liu, G., Jarrard, D. F., Hahn, N. M., Shevrin, D. H., Dreicer, R., Hussain, M., Eisenberger, M., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.3657 · Cited by 1,104
Self-citationProstate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Parker, C., Castro, E., Fizazi, K., Heidenreich, A., Ost, P., Procopio, G., Tombal, B., & Gillessen, S. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.06.011 · Cited by 977
Self-citationDarolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer
Fizazi, K., Shore, N., Tammela, T. L., Ulys, A., Vjaters, E., Polyakov, S., Jievaltas, M., Luz, M., Alekseev, B., Kuss, I., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1815671 · Cited by 930
Self-citationFizazi, K., Tran, N., Fein, L., Matsubara, N., Rodriguez-Antolin, A., Alekseev, B. Y., Özgüroğlu, M., Ye, D., Feyerabend, S., Protheroe, A., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30082-8 · Cited by 833
Self-citationChi, K. N., Chowdhury, S., Bjartell, A., Chung, B. H., Pereira de Santana Gomes, A. J., Given, R., Juárez, A., Merseburger, A. S., Özgüroğlu, M., Uemura, H., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.03488 · Cited by 525
Self-citationClarke, N. W., Ali, A., Ingleby, F. C., Hoyle, A., Amos, C. L., Attard, G., Brawley, C. D., Calvert, J., Chowdhury, S., Cook, A., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz396 · Cited by 399
Cited by
Raychaudhuri, R., Lin, D. W., & Montgomery, R. B. (2025) · JAMA · doi:10.1001/jama.2025.0228 · Cited by 355
Updates to Advanced Prostate Cancer: AUA/SUO Guideline (2023)
Lowrance, W., Dreicer, R., Jarrard, D. F., Scarpato, K. R., Kim, S. K., Kirkby, E., Buckley, D. I., Griffin, J. C., & Cookson, M. S. (2023) · Journal of Urology · doi:10.1097/ju.0000000000003452 · Cited by 321
Francolini, G., Allegra, A. G., Detti, B., Di Cataldo, V., Caini, S., Bruni, A., Ingrosso, G., D'Angelillo, R. M., Alitto, A. R., Augugliaro, M., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.23.00985 · Cited by 139
Fizazi, K., & Gillessen, S. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2023.02.015 · Cited by 119
Self-citationFizazi, K., Clarke, N. W., De Santis, M., Uemura, H., Fay, A. P., Karadurmus, N., Kwiatkowski, M., Alvarez-Fernandez, C., Jiang, S., Sotelo, M., et al. (2026) · Annals of Oncology · doi:10.1016/j.annonc.2025.10.004 · Cited by 55
Self-citation
Metadata
- Authors
- Smith, M. R., Hussain, M., Saad, F., Fizazi, K., Sternberg, C. N., Crawford, E. D., Kopyltsov, E., Park, C. H., Alekseev, B., Montesa-Pino, Á., Ye, D., Parnis, F., Cruz, F., Tammela, T. L. J., Suzuki, H., Utriainen, T., Fu, C., Uemura, M., Méndez-Vidal, M. J., Maughan, B. L., Joensuu, H., Thiele, S., Li, R., Kuss, I., & Tombal, B.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2022-03-24
- Volume
- 386
- Issue
- 12
- Pages
- 1132-1142
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4213140514
- Cited by
- 977
- References
- 19
- FWCI
- 110.08
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer. https://app.cochat.ai/papers/10.1056/nejmoa2119115
- The paper
- Smith, M. R., Hussain, M., Saad, F., Fizazi, K., Sternberg, C. N., Crawford, E. D., Kopyltsov, E., Park, C. H., Alekseev, B., Montesa-Pino, Á., Ye, D., Parnis, F., Cruz, F., Tammela, T. L. J., Suzuki, H., Utriainen, T., Fu, C., Uemura, M., Méndez-Vidal, M. J., . . . Tombal, B. (2022). Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer. New England Journal of Medicine. https://doi.org/10.1056/nejmoa2119115
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.